People who reach 100 with their thinking abilities intact are not simply older versions of a typical research cohort. They are extreme survivors: individuals who have passed through decades of competing risks from infection, cancer, cardiovascular disease, autoimmunity and neurodegeneration. A new human genetics study uses that select group to ask a sharper question about healthy aging: which immune-system variants become uncommon among those who make it that far?
Published August 20 in npj Aging, the study examined the human leukocyte antigen region, or HLA. These highly variable genes help the immune system present molecular fragments to T cells, shaping recognition of both foreign material and the body’s own cells. HLA variation is already important in transplantation, drug hypersensitivity, infectious disease and autoimmunity. Its connection to cognitively healthy extreme longevity is less settled.
A comparison built around exceptional survivors
The researchers analyzed 3,632 Dutch participants after quality control: 353 cognitively healthy centenarians, with a mean age just above 101, and 3,279 healthy middle-aged controls, averaging about 63. The centenarians came from the Amsterdam UMC-led 100-plus Study, which confirms cognitive health through self-report, a knowledgeable proxy and neuropsychological testing.
Rather than scan every possible HLA signal, the team focused on 59 alleles previously associated with Alzheimer’s disease, autoimmune conditions or SARS-CoV-2 outcomes. Six were less frequent among the centenarians. Their estimated odds ratios ranged from 0.59 to 0.74, meaning carriers were less likely to appear in the cognitively healthy centenarian group than in the middle-aged comparison group.
The six signals did not represent six fully independent biological effects. Three traveled together in a class II HLA haplotype, two formed a class I haplotype, and one stood separately. Because nearby HLA variants can be inherited together, the analysis cannot always identify which member of a linked group is driving the association.
The immune signal is broader than one disease
Four of the six alleles had previously been associated with a modest increase in Alzheimer’s risk. The study’s comparison suggested that their depletion among healthy centenarians was larger than their published Alzheimer’s effect alone would predict. Other alleles carried mixtures of associations across autoimmune diseases, sometimes increasing risk for one condition while reducing it for another.
That pattern matters more than a list of supposedly “good” or “bad” genes. HLA variants tune immune recognition across a lifetime of changing exposures. An allele that is useful in one infectious, inflammatory or treatment context may carry a disadvantage in another. The new results therefore point toward immune tradeoffs, not a universal longevity genotype.
The TENS Magazine synthesis is that the centenarian comparison behaves like a cumulative filter. By age 100, the observed HLA frequencies may reflect many routes into or away from the study group: disease susceptibility, survival, cognitive resilience, treatment response and historical exposure. The design is powerful for finding combined lifetime signals, but it cannot tell which route removed a particular allele from the centenarian pool.
How this fits earlier centenarian genetics
A 2024 study in Alzheimer’s & Dementia used the same research program to examine 86 established Alzheimer’s-associated genetic variants. Cognitively healthy centenarians carried fewer risk-increasing variants and more protective variants than Alzheimer’s cases and middle-aged controls. The strongest differences concentrated around immune and cellular waste-handling pathways.
The new HLA analysis narrows that earlier observation to a particularly complex immune region and then compares each allele’s centenarian association with prior disease associations. Together, the studies support an evidence-synthesis view: exceptional cognitive aging may depend less on one protective switch than on the accumulated balance of many small advantages and avoided liabilities.
This also explains why a stand-alone HLA result is not a personal forecast. Even the authors caution that individual alleles have limited predictive value for a complex outcome such as cognitively healthy longevity. Genes interact with other genes, health care, infections, environment and behavior. The study did not produce or validate a clinical longevity score.
Important limits on the result
The HLA types were imputed from genotyping-array data rather than read directly at full genomic resolution. Although 97.5 percent of imputed genotypes passed the study’s probability threshold, future long-read sequencing could separate linked signals more precisely. The analysis also used a pre-specified false-discovery-rate threshold below 0.10, more permissive than the 0.05 threshold common in many studies.
The centenarian sample was necessarily modest and 71 percent female. The control group was decades younger, so the study contrasts extreme survivors with people who had not yet passed through the same mortality and disease filters. Restricting the analysis to participants of European ancestry reduced population-structure noise but sharply limits generalization, because HLA frequencies vary substantially across ancestries.
The TENS Magazine translation test is therefore replication across three dimensions: direct high-resolution HLA sequencing, larger centenarian cohorts with matched survival comparisons, and populations with different ancestry and exposure histories. A signal that survives all three would be more credible as aging biology rather than a feature of one cohort.
For now, the evidence level is human genetic association. No treatment was tested, no mechanism was proven in people, and no lifespan benefit was demonstrated. The useful result is a map of where to look next: not for a single longevity allele, but for how immune recognition, disease tradeoffs and survival selection combine across an unusually long human life.
Sources: npj Aging; the Amsterdam UMC 100-plus Study; Alzheimer’s & Dementia.
TENS Magazine conceptual illustration
